Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis

Lubricin, or proteoglycan 4 (PRG4), is a secreted, glycosylated protein that binds to cartilage surfaces, which functions as a boundary lubricant. The loss of lubricin from cartilage is identified as a major pathogenic factor in post-traumatic osteoarthritis (PTOA) that has now been the aim of thera...

Full description

Bibliographic Details
Main Author: Choe, Hyeong Hun
Other Authors: Martin, James A.
Format: Others
Language:English
Published: University of Iowa 2015
Subjects:
Online Access:https://ir.uiowa.edu/etd/1836
https://ir.uiowa.edu/cgi/viewcontent.cgi?article=5893&context=etd
id ndltd-uiowa.edu-oai-ir.uiowa.edu-etd-5893
record_format oai_dc
spelling ndltd-uiowa.edu-oai-ir.uiowa.edu-etd-58932019-10-13T04:48:16Z Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis Choe, Hyeong Hun Lubricin, or proteoglycan 4 (PRG4), is a secreted, glycosylated protein that binds to cartilage surfaces, which functions as a boundary lubricant. The loss of lubricin from cartilage is identified as a major pathogenic factor in post-traumatic osteoarthritis (PTOA) that has now been the aim of therapeutic intervention. Intra-articular injection of PRG4 protein provides short-term benefits that might be extended using sustained delivery methods such as in gene therapy. Here we describe the development and testing of such therapy using adeno-associated virus (AAV) as a vector for the transfer of PRG4-green fluorescent protein (GFP) fusion gene. Our recombinant PRG4 gene produces a PRG4-GFP fusion protein to facilitate tracking of its expression and distribution on joint surfaces. We hypothesized that PRG4-GFP is fully functional as a cartilage lubricant and that PRG4-GFP produced in vivo is expressed by synoviocytes and other joint cells, and cartilage surfaces remained coated for several weeks up to months after intra-articular injection of the virus. PRG4-GFP showed lubricin-like cartilage binding in vitro, and lubrication immunoblot analysis confirmed that purified PRG4-GFP from cultured media conditioned by PRG4-GFP-transduced synoviocytes was heavily glycosylated, while confocal microscopy revealed binding of the fluorescent fusion protein to cartilage surfaces. Metal-on-cartilage friction tests showed that PRG4-GFP reduced friction coefficients to a degree comparable to that of synovial fluid and had strong chondro-protective effects in explanted cartilage exposed to shear loading. The chondrocyte viability after shear loading showed that PRG4-GFP had a strong chondro-protective effect on par with that of the synovial fluid. Confocal microscopy and immunohistology confirmed that cartilage surfaces in the stifle joints of mice injected with viruses were coated with PRG4-GFP for up to 2 or 4 weeks after the treatment. The overexpression of PRG4-GFP and coating of cartilage surfaces in the stifle joints of mice injected with Adeno-Associated Virus for the transfer of PRG4-GFP fusion gene (AAV-PRG4-GFP) was confirmed by confocal microscopy and immunohistology for up to 2 or 4 weeks post-injection. The μCT imaging and immunohistology in AAV-PRG4-GFP injected rabbit knees showed stronger inhibition in degeneration of damaged tissues than in AAV-GFP injected control group. Collectively these findings indicate that AAV-PRG4-GFP transduction is a valuable new tool for evaluating the effects of long-term lubricant supplementation on PTOA in animal models. 2015-07-01T07:00:00Z dissertation application/pdf https://ir.uiowa.edu/etd/1836 https://ir.uiowa.edu/cgi/viewcontent.cgi?article=5893&context=etd Copyright 2015 Hyeong Hun Choe Theses and Dissertations eng University of IowaMartin, James A. publicabstract Friction coefficient Gene therapy Green fluorescent protein Lubricin Osteoarthritis PRG4 Biomedical Engineering and Bioengineering
collection NDLTD
language English
format Others
sources NDLTD
topic publicabstract
Friction coefficient
Gene therapy
Green fluorescent protein
Lubricin
Osteoarthritis
PRG4
Biomedical Engineering and Bioengineering
spellingShingle publicabstract
Friction coefficient
Gene therapy
Green fluorescent protein
Lubricin
Osteoarthritis
PRG4
Biomedical Engineering and Bioengineering
Choe, Hyeong Hun
Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
description Lubricin, or proteoglycan 4 (PRG4), is a secreted, glycosylated protein that binds to cartilage surfaces, which functions as a boundary lubricant. The loss of lubricin from cartilage is identified as a major pathogenic factor in post-traumatic osteoarthritis (PTOA) that has now been the aim of therapeutic intervention. Intra-articular injection of PRG4 protein provides short-term benefits that might be extended using sustained delivery methods such as in gene therapy. Here we describe the development and testing of such therapy using adeno-associated virus (AAV) as a vector for the transfer of PRG4-green fluorescent protein (GFP) fusion gene. Our recombinant PRG4 gene produces a PRG4-GFP fusion protein to facilitate tracking of its expression and distribution on joint surfaces. We hypothesized that PRG4-GFP is fully functional as a cartilage lubricant and that PRG4-GFP produced in vivo is expressed by synoviocytes and other joint cells, and cartilage surfaces remained coated for several weeks up to months after intra-articular injection of the virus. PRG4-GFP showed lubricin-like cartilage binding in vitro, and lubrication immunoblot analysis confirmed that purified PRG4-GFP from cultured media conditioned by PRG4-GFP-transduced synoviocytes was heavily glycosylated, while confocal microscopy revealed binding of the fluorescent fusion protein to cartilage surfaces. Metal-on-cartilage friction tests showed that PRG4-GFP reduced friction coefficients to a degree comparable to that of synovial fluid and had strong chondro-protective effects in explanted cartilage exposed to shear loading. The chondrocyte viability after shear loading showed that PRG4-GFP had a strong chondro-protective effect on par with that of the synovial fluid. Confocal microscopy and immunohistology confirmed that cartilage surfaces in the stifle joints of mice injected with viruses were coated with PRG4-GFP for up to 2 or 4 weeks after the treatment. The overexpression of PRG4-GFP and coating of cartilage surfaces in the stifle joints of mice injected with Adeno-Associated Virus for the transfer of PRG4-GFP fusion gene (AAV-PRG4-GFP) was confirmed by confocal microscopy and immunohistology for up to 2 or 4 weeks post-injection. The μCT imaging and immunohistology in AAV-PRG4-GFP injected rabbit knees showed stronger inhibition in degeneration of damaged tissues than in AAV-GFP injected control group. Collectively these findings indicate that AAV-PRG4-GFP transduction is a valuable new tool for evaluating the effects of long-term lubricant supplementation on PTOA in animal models.
author2 Martin, James A.
author_facet Martin, James A.
Choe, Hyeong Hun
author Choe, Hyeong Hun
author_sort Choe, Hyeong Hun
title Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
title_short Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
title_full Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
title_fullStr Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
title_full_unstemmed Feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
title_sort feasibility of intra-articular adeno-associated virus-mediated proteoglycan-4 gene therapy to prevent osteoarthritis
publisher University of Iowa
publishDate 2015
url https://ir.uiowa.edu/etd/1836
https://ir.uiowa.edu/cgi/viewcontent.cgi?article=5893&context=etd
work_keys_str_mv AT choehyeonghun feasibilityofintraarticularadenoassociatedvirusmediatedproteoglycan4genetherapytopreventosteoarthritis
_version_ 1719264872758247424